Tournament: plano senior clark invitational | Round: 1 | Opponent: mckinney ln | Judge: ashley rihani
Cancherini et al. 4/30 ~(Laura, Engagement Manager @ McKinsey and Company, Joseph Lydon, Associate Partner @ McKinsey and Company, Jorge Santos Da Silva, Senior Partner at McKinsey and Company, and Alexandra Zemp, Partner at McKinsey and Company), "What’s ahead for biotech: Another wave or low tide?", McKinsey and Company, 4-30-2021, https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/whats-ahead-for-biotech-another-wave-or-low-tide~~ TDI
As the pandemic spread across the globe in early 2020, biotech leaders were initially
AND
as multi-omics tailored diets) to a multitude of health applications.
Bacchus 20 ~(James, member of the Herbert A. Stiefel Center for Trade Policy Studies, the Distinguished University Professor of Global Affairs and director of the Center for Global Economic and Environmental Opportunity at the University of Central Florida. He was a founding judge and was twice the chairman—the chief judge—of the highest court of world trade, the Appellate Body of the World Trade Organization in Geneva, Switzerland) "An Unnecessary Proposal: A WTO Waiver of Intellectual Property Rights for COVID-19 Vaccines," Cato Institute, 12-16-2020, https://www.cato.org/free-trade-bulletin/unnecessary-proposal-wto-waiver-intellectual-property-rights-covid-19-vaccines~~ TDI
At the heart of this emerging trade debate is a belief by many people worldwide
AND
as incentives, there would be less new knowledge and thus less innovation.
Biopharmaceutical innovation is key to prevent future pandemics and bioterror.
Marjanovic and Feijao 20 ~(Sonja Marjanovic, Ph.D., Judge Business School, University of Cambridge. Carolina Feijao, Ph.D. in biochemistry, University of Cambridge; M.Sc. in quantitative biology, Imperial College London; B.Sc. in biology, University of Lisbon.) "How to Best Enable Pharma Innovation Beyond the COVID-19 Crisis," RAND Corporation, 05-2020, https://www.rand.org/pubs/perspectives/PEA407-1.html~~ TDI
As key actors in the healthcare innovation landscape, pharmaceutical and life sciences companies have
AND
such public health threats to an even greater extent under improved innovation conditions.
Millett and Snyder-Beattie ‘17 ~(Piers Millett: Ph.D., Senior Research Fellow, Future of Humanity Institute, University of Oxford. Andrew Snyder-Beattie: M.S., Director of Research, Future of Humanity Institute, University of Oxford.) " Existential Risk and Cost-Effective Biosecurity," Health Security, 15(4), 08-01-2017, https://www.liebertpub.com/doi/full/10.1089/hs.2017.0028~~ TDI
In the decades to come, advanced bioweapons could threaten human existence. Although the
AND
and Japan using plague to cause an epidemic in China during WWII.27